- Home
- SYRE vs MLKN Comparison
SYRE vs MLKN Comparison
Compare SYRE & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- MLKN
- Stock Information
- Founded
- SYRE 2013
- MLKN 1905
- Country
- SYRE United States
- MLKN United States
- Employees
- SYRE 60
- MLKN N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- MLKN Office Equipment/Supplies/Services
- Sector
- SYRE Health Care
- MLKN Consumer Discretionary
- Exchange
- SYRE Nasdaq
- MLKN Nasdaq
- Market Cap
- SYRE 1.3B
- MLKN 1.5B
- IPO Year
- SYRE 2016
- MLKN N/A
- Fundamental
- Price
- SYRE $21.29
- MLKN $22.24
- Analyst Decision
- SYRE Strong Buy
- MLKN
- Analyst Count
- SYRE 8
- MLKN 0
- Target Price
- SYRE $51.50
- MLKN N/A
- AVG Volume (30 Days)
- SYRE 550.7K
- MLKN 436.6K
- Earning Date
- SYRE 03-03-2025
- MLKN 03-26-2025
- Dividend Yield
- SYRE N/A
- MLKN 3.40%
- EPS Growth
- SYRE N/A
- MLKN 36.08
- EPS
- SYRE N/A
- MLKN 0.91
- Revenue
- SYRE N/A
- MLKN $3,593,100,000.00
- Revenue This Year
- SYRE $168.62
- MLKN $4.29
- Revenue Next Year
- SYRE $47.61
- MLKN $4.62
- P/E Ratio
- SYRE N/A
- MLKN $24.31
- Revenue Growth
- SYRE N/A
- MLKN N/A
- 52 Week Low
- SYRE $20.13
- MLKN $20.89
- 52 Week High
- SYRE $47.97
- MLKN $31.73
- Technical
- Relative Strength Index (RSI)
- SYRE 40.66
- MLKN 47.66
- Support Level
- SYRE $21.61
- MLKN $22.25
- Resistance Level
- SYRE $23.04
- MLKN $22.98
- Average True Range (ATR)
- SYRE 1.43
- MLKN 0.58
- MACD
- SYRE -0.03
- MLKN 0.08
- Stochastic Oscillator
- SYRE 22.03
- MLKN 58.88
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.